Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 18/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.55 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.46 |
| ▸ | MELK | Q14680 | 3/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | ULK1 | O75385 | 1/20 | 0.46 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.46 |
| ▸ | STK10 | O94804 | 1/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | PAK4 | O96013 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | FES | P07332 | 1/20 | 0.46 |
| ▸ | YES1 | P07947 | 1/20 | 0.46 |
| ▸ | LYN | P07948 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8828193 | 0.92 | CHEK1 (0.56) | CHEK1KCNH2CDK2AP1 | |
| SCHEMBL16560410 | 0.89 | CHEK1 (0.45) | CHEK1KCNH2CDK2AP1MELKPLK4 | |
| SCHEMBL29900038 | 0.87 | CHEK1 (0.68) | CHEK1KCNH2CDK2AP1 | |
| SCHEMBL27768326 | 0.87 | CHEK1 (0.68) | CHEK1KCNH2CDK2AP1 | |
| SCHEMBL4343133 | 0.87 | CHEK1 (0.68) | CHEK1KCNH2CDK2AP1 | |
| SCHEMBL29900120 | 0.87 | CHEK1 (0.68) | CHEK1KCNH2CDK2AP1 | |
| SCHEMBL8846947 | 0.87 | CHEK1 (0.56) | CHEK1KCNH2 | |
| SCHEMBL8828350 | 0.87 | CHEK1 (0.51) | CHEK1KCNH2CDK2AP1 | |
| Hydrochloric Acid SCHEMBL27747351 | 0.86 | CHEK1 (0.67) | CHEK1KCNH2CDK2AP1 | |
| SCHEMBL16405053 | 0.84 | CHEK1 (0.42) | CHEK1KCNH2MELKPLK4GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487539-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | SHANGHAI HUAYU BIOTECH CO., LTD (CN) | 2016-11-08 | — | — | US | disclosed |
| US-9487539-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | SHANGHAI HUAYU BIOTECH CO., LTD (CN) | 2016-11-08 | — | — | US | disclosed |
| EP-2826780-B1 | Thieno[2,3-d]pyridazine derivatives and therapeutic use thereof for protein kinase inhibition | WU ZHANGGUI (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-2826780-B1 | Thieno[2,3-d]pyridazine derivatives and therapeutic use thereof for protein kinase inhibition | WU ZHANGGUI (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20150072987-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD (CN) | 2015-03-12 | — | — | US | disclosed |
| US-20150072987-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD (CN) | 2015-03-12 | — | — | US | disclosed |
| EP-2826780-A1 | Thieno[2,3-d]pyridazine derivatives and therapeutic use thereof for protein kinase inhibition | Wu, Zhanggui (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2826780-A1 | Thieno[2,3-d]pyridazine derivatives and therapeutic use thereof for protein kinase inhibition | Wu, Zhanggui (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8815863-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2014-08-26 | — | — | US | disclosed |
| US-8815863-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2014-08-26 | — | — | US | disclosed |
| EP-2477496-B1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-2477496-B1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20120232082-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2012-09-13 | — | — | US | disclosed |
| US-20120232082-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2012-09-13 | — | — | US | disclosed |
| EP-2477496-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | Wu, Zhanggui (US) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011035077-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011035077-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072987-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | CHEK2, CHEK1, PLK1 | CHEK1 2/4885KCNH2 4177/4885CDK2AP1 66/4885 |
| US-20120232082-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | CHEK2, CHEK1, BUB1B | CHEK1 2/4885KCNH2 4004/4885CDK2AP1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.